(Q38022144)

27 August 2017

Pharmacogenomic approaches to study the effects of antihypertensive drugs (English)

1 reference

27 August 2017

1 reference

3

1 reference

27 August 2017

Kei Kamide

1

1 reference

PubMed ID

22739423

27 August 2017

Yuhei Kawano

series ordinal

2

1 reference

27 August 2017

28 June 2012

1 reference

27 August 2017

Hypertension Research

1 reference

27 August 2017

35

1 reference

27 August 2017

8

1 reference

27 August 2017

796-799

1 reference

https://scigraph.springernature.com/pub.10.1038/hr.2012.82

27 August 2017

0 references

cites work

Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Genes and hypertension: from gene mapping in experimental models to vascular gene transfer strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Genetic basis of hypertension for the development of tailored medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Linkage of the Angiotensinogen Gene to Essential Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

High-density association study and nomination of susceptibility genes for hypertension in the Japanese National Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Common variants in the ATP2B1 gene are associated with susceptibility to hypertension: the Japanese Millennium Genome Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Antihypertensive pharmacogenetics: getting the right drug into the right patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Pharmacogenomics of antihypertensive drugs: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Angiotensinogen gene variation and renoprotective efficacy of renin-angiotensin system blockade in IgA nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Polymorphisms and haplotypes of the regulator of G protein signaling-2 gene in normotensives and hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: the genetics of hypertension associated treatment study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Warfarin pharmacogenetics: a rising tide for its clinical value

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

7 January 2021

Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men : the Suita Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

7 January 2021

Identification of hypertension-susceptibility genes and pathways by a systemic multiple candidate gene approach: the millennium genome project for hypertension

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

7 January 2021

Promoter Polymorphism of RGS2 Gene Is Associated with Change of Blood Pressure in Subjects with Antihypertensive Treatment: The Azelnidipine and Temocapril in Hypertensive Patients with Type 2 Diabetes Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

7 January 2021

Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

7 January 2021

Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

7 January 2021

Study Design of HOMED-BP: Hypertension Objective Treatment Based on Measurement by Electrical Devices of Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

7 January 2021

Integrating pharmacogenetics into gemcitabine dosing--time for a change?

1 reference

https://api.crossref.org/works/10.1038%2FHR.2012.82

7 January 2021

Identifiers

DOI

10.1038/HR.2012.82

1 reference

27 August 2017

1 reference

PubMed ID

22739423